June 17, 2014
by inesp.alves
2 Comments
Dan Oppenheimer, Group Vice President, Development & Portfolio Strategy – BioMarin Pharmaceutical Inc, presented today at the Wells Fargo research conferences the actual state of art of BioMarin´s drugs under evaluation, including BMN-111. Has said, BioMarin predicts to have results from … Continue reading
April 20, 2014
by inesp.alves
2 Comments
BMN 111 Clinical Studies in Achondroplasia (information by: BioMarin) 1-Double-Blind, Placebo-Controlled Phase 1 Study (Protocol 111-101) Results of a two-part, double-blind, placebo-controlled Phase 1 study (Protocol 111-101) conducted in 48 healthy adult volunteers demonstrated that systemic exposure to BMN … Continue reading